by Mark Chiang

马克·蒋

Share To

分享到

iTeos Therapeutics announced plans to discontinue its TIGIT program following disappointing clinical results. The decision comes after the company faced setbacks in advancing its experimental immunotherapy, which was designed to target TIGIT, a protein believed to play a role in suppressing immune responses against cancer.

iTeos Therapeutics 宣布计划在令人失望的临床结果后终止其 TIGIT 项目。这一决定是在公司推进其旨在靶向 TIGIT 的实验性免疫疗法时遭遇挫折之后做出的，TIGIT 是一种被认为在抑制针对癌症的免疫反应中起作用的蛋白质。

The move marks a significant shift for iTeos, which had previously invested heavily in the development of this approach..

这一举动标志着iTeos的重大转变，该公司此前已在该方法的开发上投入了大量资金。

The announcement is part of broader updates within the biotech sector. Other developments include progress from Intellia Therapeutics and Keros Therapeutics on their respective research initiatives. Additionally, Vivodyne has reported advancements in its organ-on-a-chip technology, while Merck continues to expand operations in China.

该公告是生物技术领域更广泛更新的一部分。其他进展包括Intellia Therapeutics和Keros Therapeutics在各自研究项目上取得的进展。此外，Vivodyne报告了其器官芯片技术的进步，而默克继续扩大在中国的业务。

Daiichi Sankyo also shared updates on its pipeline projects. These announcements reflect ongoing activity across various areas of biotechnology as companies navigate challenges and pursue innovation..

第一三共还分享了其研发管线项目的最新进展。这些公告反映了生物技术各个领域正在进行的活动，因为企业正在应对挑战并追求创新。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

Date: May 29, 2025

日期：2025年5月29日

Related posts:

相关文章：

Layoffs Impact Drug Development; FDA Staff Reductions Raise Concerns Over Institutional Knowledge Loss

裁员影响药物开发；FDA员工减少引发对机构知识流失的担忧

Former HHS Official Micky Tripathi to Lead AI Implementation at Mayo Clinic

前HHS官员米基·特里帕蒂将领导梅奥诊所的AI实施工作

Generic Drug Pricing: Market Research and Data-Driven Strategies Key to Competitive Advantage, Study Finds

研究发现：通用药物定价：市场调研和数据驱动策略是获得竞争优势的关键

Stage III Melanoma Treatment Advances Focus on Enhancing Immune Response

第三阶段黑色素瘤治疗进展聚焦于增强免疫反应

©www.geneonline.com All rights reserved. Collaborate with us:

©www.geneonline.com 版权所有。与我们合作：

[email protected]

[email protected]

Author

作者

Mark Chiang

蒋志光

Related Post

相关文章

News Flash

新闻快讯

Virginia Tech Researchers Develop Peptide Drug to Target Glioblastoma Tumor Recurrence

弗吉尼亚理工大学研究人员开发出靶向胶质母细胞瘤复发的肽类药物

2025-05-29

2025年5月29日